WuXi Biologics (Cayman) Inc

CN

WXBGHU

Health Care

3.24 ₽

Current price

Strong buy
3.24 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    43 / 240

  • Position in country

    3016 / 7387

  • Return on Assets, %

    6.8

    -2.7

  • Net income margin, %

    14.4

    -6.7

  • EBITDA margin, %

    30.8

    5.6

  • Debt to Equity, %

    11.3

    15.1

  • Intangible assets and goodwill, %

    3.6

    4.7

  • Revenue CAGR 3Y, %

    44.7

    12.8

  • Revenue Y, % chg

    5.7

    0

  • P/E

    16.6

    32.1

  • P/BV

    1.3

    2

  • P/S

    3.2

    4.1

  • EV/S

    3

    3.6

  • EV/EBITDA

    8.9

    7.8

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    -5.7

    48.9

  • Forward P/E

    11.8

    25.5

  • Expected dividend per share

    0

    0

  • Payout Ratio, %

    0

    10.1

Get an analytical review of this company

Competitors

Ranks

  • WuXi AppTec Co Ltd

    00%

  • Pharmaron Beijing Co Ltd

    00%

  • WuXi XDC Cayman Inc

    00%

  • Hangzhou Bio-Sincerity Pharma-Tech Co Ltd

    00%

  • Joinn Laboratories China Co Ltd

    00%

  • WuXi Biologics (Cayman) Inc

    00%

  • Genscript Biotech Corp

    00%

  • Shanghai Runda Medical Technology Co Ltd

    00%

  • Hangzhou Tigermed Consulting Co Ltd

    00%

  • MGI Tech Co Ltd

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    China

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Life Sciences Tools & Services

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    7553

  • Ticker

    WXXWY.PK

  • ISIN

    US98260N1081

  • IPO date

    2017-06-13

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-03-27

  • Date fact. publication of reports

    2023-12-31

Company Description

WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing of biologics services. The Company's technology platforms include WuXiBody TM bispecific antibody technology platform and antibody drug conjugates (ADC) technology platform. It has brought in several new projects into its pipeline. The Company has a vaccine manufacturing facility and produces vaccines for customers to supply the global market. The Company conducts its businesses within the China market and to overseas markets, such as North America, Europe and other markets.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: